Edition internationale

HEPATITIS B AND D PROTOCOLS

HAMATAKE, ROBERT K

ISBN 10: 1588291057 ISBN 13: 9781588291059
Edité par SPRINGER, 2004
Neuf(s) Hardcover

Vendeur UK BOOKS STORE, London, LONDO, Royaume-Uni Évaluation du vendeur 5 sur 5 étoiles Evaluation 5 étoiles, En savoir plus sur les évaluations des vendeurs

Vendeur AbeBooks depuis 11 mars 2024


A propos de cet article

Description :

Brand New! Fast Delivery This is an International Edition and ship within 24-48 hours. Deliver by FedEx and Dhl, & Aramex, UPS, & USPS and we do accept APO and PO BOX Addresses. Order can be delivered worldwide within 7-12 days and we do have flat rate for up to 2LB. Extra shipping charges will be requested if the Book weight is more than 5 LB. This Item May be shipped from India, United states & United Kingdom. Depending on your location and availability. N° de réf. du vendeur Ad 9781588291059

Signaler cet article

Synopsis :

Despite the availability of an effective vaccine, there are still 400 million people, worldwide who are chronically infected with hepatitis B virus (HBV). For them, the vaccine, as currently applied, has no value. Given the possible consequences of HBV infection, the number of those chronically infected with HBV presents an enormous public health challenge. For example, the major etiology of hepatocellular carcinoma (HCC) is chronic infection with HBV. Although fifth in cancer incidence, worldwide, HCC/liver cancer is the third leading cause of cancer death. The high mortality as- ciated with HCC arises because the disease is often detected late and is unresponsive to treatment. The number of deaths caused by PHCC is expected to rise over the next 20 years. Those chronically infected with HBV have a life risk of death to HCC of between 10 and 25%. Even the limited efficacy of drugs for the treatment of chronic HBV helps underscore the point that this disease is responsive to therapy. Drugs that target the polymerase (e. g., hepsera and lamivudine) and interferon alpha represent two distinct strategies and show that both conventional antiviral and immunothe- peutic approaches can be used in management. However, the current inventory of therapeutics is inadequate. Interferon alpha is of limited value, only parenterally ava- able, and fraught with adverse reactions.

Les informations fournies dans la section « A propos du livre » peuvent faire référence à une autre édition de ce titre.

Détails bibliographiques

Titre : HEPATITIS B AND D PROTOCOLS
Éditeur : SPRINGER
Date d'édition : 2004
Reliure : Hardcover
Etat : New
Edition : Edition internationale

Meilleurs résultats de recherche sur AbeBooks

There are 5 autres exemplaires de ce livre sont disponibles

Afficher tous les résultats pour ce livre